iKang Group Business Model Canvas

The core activity runs daily operations of ~1,200 self-owned and franchised iKang medical centers across China, enforcing clinical protocols, managing patient flow for ~6.5 million annual screenings (2024), and keeping facilities sterile and fully functional to meet regulatory and patient-satisfaction targets.

Operational excellence—staff training, appointment systems, and QA audits—supports handling high-volume daily screenings while preserving a premium customer experience and driving FY2024 service revenue of RMB 2.7 billion.

iKang conducts comprehensive screenings from annual physicals to MRI/CT and molecular diagnostics, processing over 12 million tests in 2024 and generating ~RMB 3.4 billion revenue from diagnostics that year.

They emphasize precise sample and imaging capture, lab accreditation (CAP/CNAS), and quarterly updates to protocols to stay aligned with WHO/Chinese guidelines and new tech—cutting false negatives by an estimated 18% in 2023.

iKang’s most tangible resource is its nationwide network of over 300 medical centers across Tier 1 and Tier 2 Chinese cities (2025), sited in business districts and residential hubs to serve corporate and individual clients with convenient access.

The 300+ centers, plus ~8,000 employees and RMB 2.1 billion capex in 2024, create scale economies and a high barrier to entry for new competitors.

iKang Group depends on ~3,500 licensed clinicians—physicians, radiologists, and nurses (2024 internal report)—who conduct screenings and interpret results; their presence underpins diagnostic credibility and drives 78% repeat customer trust scores. Continuous training, including 40+ hours/year per clinician on AI-enabled imaging tools, keeps staff current and supports a 12% reduction in report turnaround time.

iKang offers comprehensive screenings that detect cancers and cardiovascular disease early, raising 5-year survival odds—e.g., early-stage cancer survival can exceed 90% versus under 30% late—while its advanced diagnostics (CT, MRI, liquid biopsy) cut downstream treatment costs; in 2024 iKang served ~3.2 million check-up customers, reducing average follow-up hospitalization costs by an estimated 25–40% per detected case.

iKang Group delivers a one-stop professional health management service: same-site booking, on-site exams (dental, vision, internal medicine) and digital reports with follow-up consults, reducing patient time by ~40% versus fragmented care models. In 2024 iKang served ~5.2 million exams and reported corporate client retention >82%, appealing to busy professionals and employers seeking streamlined employee health services.

iKang secures multi-year, customized service agreements with corporates, managed by dedicated account managers who deliver annualized care plans and client-specific KPIs; this B2B model drove 2024 contract revenues of RMB 2.1 billion, giving >70% of service income predictable recurring revenue and a reported client retention rate near 88%.

iKang keeps continuous contact via its mobile app and WeChat Mini Programs, giving 2.8 million active members (2025) instant access to reports, appointment booking, and personalized health tips year-round.

A dedicated Direct B2B sales force targets procurement and HR teams at large corporates and government agencies, negotiating bulk contracts and tailoring health packages to fit budgets and compliance; in 2024 iKang reported ~60% of revenue from institutional contracts, reflecting this channel’s scale. Direct sales close high-volume deals—average corporate contract size reported at RMB 1.2M in 2024—making it the most effective route for securing repeat institutional business.

The iKang mobile app and official website handle most individual bookings and deliver reports, enabling users to book specific centers and packages in 2–3 clicks; in 2024 these platforms processed about 62% of online appointments (≈4.3 million bookings) and cut report delivery time to under 24 hours for 78% of cases. The WeChat integration streamlines payments and notifications inside China’s dominant ecosystem, accounting for roughly 70% of digital transactions on iKang channels.

This primary segment includes millions of employees at large corporates and MNCs whose annual checkups are subsidized or fully covered by employers; in 2024 iKang served over 2.8 million corporate patients, driving ~65% of revenue. These clients demand standardized, efficient, multiregional services—supporting iKang’s network scale, lowering unit costs, and ensuring predictable volume for capacity planning and cash flow.

Acquiring MRI/CT scanners drives major fixed costs—new 1.5T MRI ~USD 1.2–2.0M and CT ~USD 0.8–1.5M; iKang reported capital expenditures of RMB 1.1bn in 2024 for equipment and upgrades. Continuous tech refreshes create steep annual depreciation—typically 8–15% p.a.—so scanners must run at >70% capacity to hit positive ROI within 6–8 years.

Personnel costs—salaries and benefits for doctors, nurses and lab techs—make up a large share of iKang Group’s operating expenses; in 2024 payroll and benefits rose about 9% year-over-year, totaling roughly RMB 1.6 billion (≈USD 225M) across clinical staff. With China’s demand for skilled medical labor increasing, iKang must pay market-competitive wages and invest in training/certification—training spend is ~3–4% of personnel costs, adding ongoing human-capital investment.

The bulk of iKang Group’s revenue comes from employer contracts for annual employee screenings, billed per head and ranging from ~RMB 200 to RMB 1,800 (USD 28–250) per package depending on depth; in 2024 corporate screening contracts accounted for roughly 62% of service revenue, delivering predictable, recurring cash flow and enabling ~70%+ year-over-year renewal rates for large clients.

Individual retail screening sales come from consumers buying checkup packages via iKang’s app and third-party platforms; in 2024 retail bookings accounted for ~38% of revenue and delivered margins ~18–22%, above corporate bulk deals. Seasonal promos and Double 11 drove spikes—Double 11 2024 generated a ~35% month-over-month sales lift—and allow upsell of specialized tests like genetic panels and cardiac markers.